1141174724 Complement activation induces dysregulation of angiogenic factors and causes fetal loss

2006 ◽  
Vol 55 (6) ◽  
pp. 396-397 ◽  
Author(s):  
G Girardi ◽  
D Yarilin ◽  
JM Thurman ◽  
VM Holers ◽  
JE Salmon
2002 ◽  
Vol 195 (2) ◽  
pp. 211-220 ◽  
Author(s):  
V. Michael Holers ◽  
Guillermina Girardi ◽  
Lian Mo ◽  
Joel M. Guthridge ◽  
Hector Molina ◽  
...  

The antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, vascular thrombosis, and thrombocytopenia occurring in the presence of antiphospholipid (aPL) antibodies. The pathogenesis of fetal loss and tissue injury in APS is incompletely understood, but is thought to involve platelet and endothelial cell activation as well as procoagulant effects of aPL antibodies acting directly on clotting pathway components. Recent studies have shown that uncontrolled complement activation in the placenta leads to fetal death in utero. We hypothesized that aPL antibodies activate complement in the placenta, generating split products that mediate placental injury and lead to fetal loss and growth retardation. To test this hypothesis, we used a murine model of APS in which pregnant mice are injected with human IgG containing aPL antibodies. We found that inhibition of the complement cascade in vivo, using the C3 convertase inhibitor complement receptor 1–related gene/protein y (Crry)-Ig, blocks fetal loss and growth retardation. Furthermore, mice deficient in complement C3 were resistant to fetal injury induced by aPL antibodies. While antigenic epitopes recognized by aPL antibodies are important in the pathogenesis of APS, our data show that in vivo complement activation is required for aPL antibody-induced fetal loss and growth retardation.


2004 ◽  
Vol 10 (11) ◽  
pp. 1222-1226 ◽  
Author(s):  
Guillermina Girardi ◽  
Patricia Redecha ◽  
Jane E Salmon

2006 ◽  
Vol 203 (9) ◽  
pp. 2165-2175 ◽  
Author(s):  
Guillermina Girardi ◽  
Dmitry Yarilin ◽  
Joshua M. Thurman ◽  
V. Michael Holers ◽  
Jane E. Salmon

Immune mechanisms have been implicated in placental dysfunction in patients with recurrent miscarriages and intrauterine growth restriction (IUGR), but the mediators are undefined. Here we show that complement activation, particularly C5a, is a required intermediary event in the pathogenesis of placental and fetal injury in an antibody-independent mouse model of spontaneous miscarriage and IUGR, and that complement activation causes dysregulation of the angiogenic factors required for normal placental development. Pregnancies complicated by miscarriage or growth restriction were characterized by inflammatory infiltrates in placentas, functional deficiency of free vascular endothelial growth factor (VEGF), elevated levels of soluble VEGF receptor 1 (sVEGFR-1, also known as sFlt-1; a potent anti-angiogenic molecule), and defective placental development. Inhibition of complement activation in vivo blocked the increase in sVEGFR-1 and rescued pregnancies. In vitro stimulation of monocytes with products of the complement cascade directly triggered release of sVEGFR-1, which sequesters VEGF. These studies provide the first evidence linking the complement system to angiogenic factor imbalance associated with placental dysfunction, and identify a new effector of immune-triggered pregnancy complications.


2008 ◽  
Vol 45 (16) ◽  
pp. 4117
Author(s):  
Anne Lynch ◽  
James Murphy ◽  
Richard Levine ◽  
Ronald Gibbs ◽  
Patricia Giclas ◽  
...  

2011 ◽  
Vol 225 (4) ◽  
pp. 502-511 ◽  
Author(s):  
Danielle Cohen ◽  
Aletta Buurma ◽  
Natascha N Goemaere ◽  
Guillermina Girardi ◽  
Saskia le Cessie ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document